239 related articles for article (PubMed ID: 54923)
21. C3 requirements for formation of alternative pathway C5 convertase.
Daha MR; Fearon DT; Austen KF
J Immunol; 1976 Aug; 117(2):630-4. PubMed ID: 950465
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library.
Sahu A; Kay BK; Lambris JD
J Immunol; 1996 Jul; 157(2):884-91. PubMed ID: 8752942
[TBL] [Abstract][Full Text] [Related]
23. Complement: activation, consequences, and control.
James K
Am J Med Technol; 1982 Sep; 48(9):735-42. PubMed ID: 6215861
[TBL] [Abstract][Full Text] [Related]
24. C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase.
Daha MR; Fearon DT; Austen KF
J Immunol; 1976 Jan; 116(1):1-7. PubMed ID: 1245733
[TBL] [Abstract][Full Text] [Related]
25. The role of C1s, C1r and properdin in the initiation of the C3b-dependent feedback mechanism of the complement system.
Johnson U
Acta Pathol Microbiol Scand C; 1978 Apr; 86(2):73-8. PubMed ID: 696332
[TBL] [Abstract][Full Text] [Related]
26. The alternative pathway of complement activation.
Götze O; Müller-Eberhard HJ
Adv Immunol; 1976; 24():1-35. PubMed ID: 798473
[No Abstract] [Full Text] [Related]
27. The interaction of glycoprotein C of herpes simplex virus types 1 and 2 with the alternative complement pathway.
Hung SL; Peng C; Kostavasili I; Friedman HM; Lambris JD; Eisenberg RJ; Cohen GH
Virology; 1994 Sep; 203(2):299-312. PubMed ID: 8053154
[TBL] [Abstract][Full Text] [Related]
28. The properdin pathway: mechanisms of complement activation and analogies to the classical pathway.
Fearon DT; Austen KF; Ruddy S
Rheumatology; 1975; 6():2-16. PubMed ID: 1105744
[No Abstract] [Full Text] [Related]
29. Molecular basis of complement resistance of human melanoma cells expressing the C3-cleaving membrane protease p65.
Ollert MW; Kadlec JV; Petrella EC; Bredehorst R; Vogel CW
Cancer Res; 1993 Feb; 53(3):592-9. PubMed ID: 8425193
[TBL] [Abstract][Full Text] [Related]
30. Interaction of zymosan and of activated properdin with factor D-depleted guinea pig serum: implications for the mechanism of initial C3 cleavage via the alternative complement pathway.
Brade V; Bentley C; Bitter-Suermann D; Hadding U
Z Immunitatsforsch Immunobiol; 1977 Feb; 152(5):402-14. PubMed ID: 556571
[TBL] [Abstract][Full Text] [Related]
31. Alternative pathway complement activation in rheumatoid arthritis.
El-Ghobarey A; Whaley K
J Rheumatol; 1980; 7(4):453-60. PubMed ID: 6158571
[TBL] [Abstract][Full Text] [Related]
32. Analysis of the interaction between properdin and factor B, components of the alternative-pathway C3 convertase of complement.
Farries TC; Lachmann PJ; Harrison RA
Biochem J; 1988 Aug; 253(3):667-75. PubMed ID: 3140783
[TBL] [Abstract][Full Text] [Related]
33. Binding of properdin to solid-phase immune complexes: critical role of the classical activation pathway of complement.
Junker A; Baatrup G; Svehag SE; Wang P; Holmström E; Sturfelt G; Sjöholm AG
Scand J Immunol; 1998 May; 47(5):481-6. PubMed ID: 9627133
[TBL] [Abstract][Full Text] [Related]
34. Binding of activated properdin to untreated erythrocytes: a new function of activated properdin.
Konno T; Hirai H; Tamura N
Immunology; 1978 Feb; 34(2):207-15. PubMed ID: 627406
[TBL] [Abstract][Full Text] [Related]
35. Cleavage of the third complement component (C3) and generation of the spasmogenic peptide, C3a, in human serum via the properdin pathway: demonstration of inhibitory as well as enhancing effects of epsilon-amino-caproic acid.
Vogt W; Schmidt G; Lynen R; Dieminger L
J Immunol; 1975 Feb; 114(2 Pt 1):671-7. PubMed ID: 804510
[TBL] [Abstract][Full Text] [Related]
36. Complement fixation by solid phase immune complexes. Reduced capacity in SLE sera.
Baatrup G; Jonsson H; Sjöholm A; Sturfelt G; Svehag SE
J Clin Lab Immunol; 1988 Jun; 26(2):73-9. PubMed ID: 3264027
[TBL] [Abstract][Full Text] [Related]
37. Chemotactic activity derived from interaction of factors D and B of the properdin pathway with cobra venom factor or C3B.
Ruddy S; Austen KF; Goetzl EJ
J Clin Invest; 1975 Mar; 55(3):587-92. PubMed ID: 1167871
[TBL] [Abstract][Full Text] [Related]
38. Babesia rodhaini: requirement of complement for penetration of human erythrocytes.
Chapman WE; Ward PA
Science; 1977 Apr; 196(4285):67-70. PubMed ID: 841340
[TBL] [Abstract][Full Text] [Related]
39. Pathways of complement activation in membranoproliferative glomerulonephritis and allograft rejection.
Fearon DT; Daha MR; Strom TB; Weiler JM; Carpenter CB; Austen KF
Transplant Proc; 1977 Mar; 9(1):729-39. PubMed ID: 325806
[TBL] [Abstract][Full Text] [Related]
40. Activation of the complement and properdin systems in rheumatoid arthritis.
Ruddy S; Austen KF
Ann N Y Acad Sci; 1975 Jun; 256():96-104. PubMed ID: 1099964
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
